Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
24
self-reported 11–50 band
Founded
2007
19 years
Legal entities
1
ABR
Office countries
2
4 addresses
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
RECCE PHARMACEUTICALS LTD
ABN73124849065
Legal entities
Show as table · Recce Pharmaceuticals Ltd: 1 registry entity
| RECCE PHARMACEUTICALS LTD | ABN 73124849065 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Specialties
All 16 specialties
- Diabetic Foot Infections
- Urinary Tract Infections
- Pharmaceuticals
- Sepsis
- Superbugs
- Polymers
- Biotech
- Synthetic Polymers
- Antibiotics
- Global Health
- Antibiotic Resistance
- Clinical Trials
- Blood Infections
- Infectious Disease
- FDA
- ASX
Locations
2
Countries with an office address4 addresses on record
AustraliaprimaryUnited States
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|---|
| Primary country | AU |
All codes: AU US
Addresses
- AUL25, 1 Farrer Place; Sydney, NSW 2000Primary
- AU3 Brodie hall Drive, Technology Park; 10; Perth, WA 6102
- AU64 Talavera Rd; 8; Macquarie Park, NSW 2113
- US1717 Pennsylvania Ave NW; Washington, District of Columbia 20006
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Recce Pharmaceuticals Ltd?
One Western Australia entity on the ABR: RECCE PHARMACEUTICALS LTD (ABN 73 124 849 065), high confidence.
How many people work at Recce Pharmaceuticals Ltd?
24 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Recce Pharmaceuticals Ltd have offices?
Four addresses on record across 2 countries. Primary: L25, 1 Farrer Place, Sydney, NSW 2000.
Has Recce Pharmaceuticals Ltd raised funding?
None linked to this brand.
What does Recce Pharmaceuticals Ltd list as its specialties?
16 tags on the brand's own list, among them polymers, asx and pharmaceuticals.
Which companies are listed alongside Recce Pharmaceuticals Ltd?
10 profiles list Recce Pharmaceuticals Ltd as a peer — 85th percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. Neuren Pharmaceuticals Limited and Mayne Pharma Australia list it back.